華檢醫療(01931.HK)2024年歸母淨利2.6億元 同比增長9.3%
格隆匯4月11日丨華檢醫療(01931.HK)公告,截至2024年12月31日止年度業績,集團實現收益人民幣31.62億元,較截至2023年12月31日止年度增長2.4%。母公司擁有人應佔溢利2.6億元,同比增長9.3%;每股盈利17.42人民幣分。增長主要歸因於集團分析儀及售後服務業務的毛利率上升。董事會不建議就2024年度派發末期股息。
透過多年營運,集團已建立龐大的分銷網絡,覆蓋中國31個省份、直轄市及自治區,醫院覆蓋範圍廣泛。截至2024年12月31日,集團於其已建立的分銷網絡中擁有351名直接客戶(包括醫院及醫療機構)以及1,253個分銷商。截至2024年12月31日,集團亦主要透過在中國的下級分銷網絡覆蓋1,674家三級醫院,進一步提升集團競爭優勢。
基於對醫療行業技術革新與市場需求的持續洞察,集團將在鞏固IVD核心業務的基礎上,進一步拓展技術創新的邊界,積極探索機器人技術及前沿技術的戰略價值,以把握全球科技變革帶來的增長機遇。展望未來,集團將藉助資本市場,繼續鞏固在中國IVD行業的領先地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.